Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SEB in connection with its SEK 15 billion rights issue
Mandate

Vinge advises SEB in connection with its SEK 15 billion rights issue

February 05, 2009

Skandinaviska Enskilda Banken AB (publ) has resolved to carry out a new share issue with preferential rights for the shareholders. Through the rights issue, which is fully committed and underwritten, the bank will raise approximately SEK 15 billion excluding transaction costs. The rights issue is subject to approval by the bank’s annual general meeting on 6 March 2009.

Vinge’s team is led by Hans Wibom and Mattias Friberg. The team also include, among others, Emil Hedberg, Petter Kjöllerström and Peter Larsson.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026